Featured

Neurogene Inc. (NYC, USA) has announced to become the first investigative treatment of both neurodegenerative and ocular disease manifestations of Batten Disease.

Neurogene Inc. based in Manhattan, New York City, has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug… Read More »Neurogene Inc. (NYC, USA) has announced to become the first investigative treatment of both neurodegenerative and ocular disease manifestations of Batten Disease.

Phase 2/3 anti-sense treatment (”QR-421a”) of retinitis pigmentosa (RP) aims to use exon skipping within the USH2A gene to repair the shortened usherin protein.

Dutch researchers at the Radboud University Medical Centre, Nijmegen, and ProQR Therapeutics, a company, based in Leiden, the Netherlands, are enrolling up to 200 patients… Read More »Phase 2/3 anti-sense treatment (”QR-421a”) of retinitis pigmentosa (RP) aims to use exon skipping within the USH2A gene to repair the shortened usherin protein.

Evidence shows smoking cessation provides a significant reduction on the risk of progressing to age-related macular (AMD) and alcohol consumption having a causal association with geographic atrophy (GA) risk. 

Researchers at the Institute of Health Informatics, University College London (UCL), and the International AMD Genomics Consortium (IAMDGC), have reported a significant study on an… Read More »Evidence shows smoking cessation provides a significant reduction on the risk of progressing to age-related macular (AMD) and alcohol consumption having a causal association with geographic atrophy (GA) risk. 

Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.

Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10